During Friday’s trading session, shares of a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products surged by around 1 percent on the BSE to Rs. 522.95, with a market cap of Rs. 2,404 crores.
Senores Pharma‘s management expects a PAT growth of at least 100 percent in the next one year, and has outlined several strategic initiatives to support this trajectory. In this article, we’ll take a closer look at the management’s outlook and highlight other important aspects of the business. The stock has delivered negative returns of nearly 7 percent over a one-year period, while delivering over 3 percent of positive returns in one month.
Management Guidance
For FY26, the company has projected a revenue growth of at least 50 percent year-on-year. It is also targeting a minimum 100 percent increase in profit after tax (PAT) from current levels. Additionally, the management stated that an EBITDA margin of 25 percent is fully sustainable and is expected to improve further.
Further, Senores Pharma plans to launch 31 ANDAs and 23 CDMO/CMO products in regulated markets for FY26. The commercialisation of recently acquired ANDAs—sourced from Dr. Reddy’s and Breckenridge—is set to begin in a phased manner starting from Q3 FY26.
The company has outlined a planned capex of Rs. 250 crore for FY26. Expansion of its oral solids manufacturing capacity is currently in progress, with a third production line being installed and a fourth line in the planning stage. Capex for the injectable facility is scheduled for the end of FY26.
Senores Pharma is also pursuing the development of a new greenfield site in India to support operations in both semi-regulated and regulated markets. Additionally, its new API facility, with a capacity of 100-120 MTPA, commenced operations in March 2025. An FDA inspection for the site is targeted for Q2 of calendar year 2026.
The company expects its emerging market business to remain more profitable and continue growing, driven by evolving product mixes. Management does not anticipate any material changes to the overall revenue mix on a steady-state annual basis. The current revenue distribution is expected to continue, with ~70 percent coming from regulated markets and 30 percent from emerging markets.
The company expects its emerging market business to remain more profitable and continue growing, driven by evolving product mixes. Management does not anticipate any material changes to the overall revenue mix on a steady-state annual basis. The current revenue distribution is expected to continue, with ~70 percent coming from regulated markets and 30 percent from emerging markets.
The company will maintain its strategic focus on three core pillars: expanding its ANDA portfolio in regulated markets, steadily scaling up its CDMO/CMO segment within regulated markets, and expanding its product portfolio while enhancing profitability in emerging markets.
Financials
Senores Pharma reported a marginal growth in its revenue from operations, showing a year-on-year rise of around 12 percent from Rs. 102 crores in Q4 FY24 to Rs. 114 crores in Q4 FY25. Similarly, its net profit increased during the same period from Rs. 14 crores to Rs. 18 crores, representing a growth of around 28 percent YoY.
In terms of key financial metrics, Senores Pharma has a Return on Equity (RoE) of 11.8 percent and a return on capital employed (RoCE) of 11.4 percent, with a debt-to-equity ratio of 0.4.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
